Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Neoplasms by Histologic Type × enzalutamide × 30 days × Clear all

Sponsor

Conditions

Prostatic Neoplasms 22 Prostatic Neoplasms, Castration-Resistant 4 Recurrence 2 Neoplasm Metastasis 2 Metastatic Castration-Resistant Prostate Cancer 2 mCRPC 1 Small Cell Lung Carcinoma 1 Prostate Cancer Metastatic 1 Prostate Adenocarcinoma 1 Primary Dysautonomias 1 Pathologic Complete Response 1 Neoplasms 1 Neoplasm, Residual 1 Metastatic Hormone-sensitive Prostate Cancer 1 Lymphoma, Follicular 1 Kidney Diseases 1 Hypertension 1 Dementia 1 Cognitive Dysfunction 1 Breast Neoplasms 1 Bites and Stings 1 Biochemically Recurrent Prostate Cancer 1

Interventions

trametinib 1 pralsetinib 1 ponatinib 1 pembrolizumab 1 fludarabine phosphate 1 fludarabine 1 durvalumab 1 dabrafenib 1 Whole-Body Irradiation 1 Tacrolimus 1 Peripheral Blood Stem Cell Transplantation 1 Pemetrexed 1 Patient Reported Outcome Measures 1 Paclitaxel 1 Mycophenolic Acid 1 Mesna 1 Melphalan 1 Immunotherapy 1 Gemcitabine 1 Cyclophosphamide 1 Cisplatin 1 Carboplatin 1 Busulfan 1 Bone Marrow Transplantation 1 Biopsy 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡